Blood Transfusion Research Center

Tehrān, Iran

Blood Transfusion Research Center

Tehrān, Iran
Time filter
Source Type

Daneshmand A.R.,Blood Transfusion Research Center | Forouzandeh H.,Ahvaz Jundishapur University of Medical Sciences | Azadi M.,Shiraz University of Medical Sciences | Cheraghzadeh Dezfuli S.,Esfahan University of Medical science
Iranian Journal of Blood and Cancer | Year: 2015

Background: This study made an attempt to make the quantitative and qualitative evaluation of hematological research output in five Islamic countries; Iran, Turkey, Malaysia, Saudi Arabia and Egypt; which have the most scientific productions from 1996-2013. Materials and Methods: The current study was carried out during the 1st to 31st of September, 2014 in Blood Transfusion Research Center, Shiraz, Iran. This bibliometric study evaluated quantities and qualities of publications on hematological researches based on SCImago Journal Ranking, for over 17 years (1996- 2013). Strategy of the research was based on the keyword “hematology “. Neither language nor document type restrictions were considered. Data were extracted, tabulated, and compared to identify the ranks as well as trends. The ranking and analyzing indicators included were: ‘number of documents’, ‘citable documents’, ‘citation’, ‘self-citation’, ‘cites per documents’, ‘H-index’, ‘sited documents’, and ‘international collaboration’ . Results: The 5 Islamic countries published a total of 6914 documents in the field of hematology in this period. This number represents 0.248 % of the total documents produced globally in the field of hematology. Results revealed an increase in the number of publications and citable documents for these countries during 1996-2013. Comparison among these countries showed that Turkey, Iran, Egypt have the highest number of documents and citable documents, respectively. Furthermore Turkey and Iran led qualitative indicators like H-index and citation. Conclusion: Despite considerable improvement in recent years these Islamic countries should further support their scientific institutes to increase the quantity and quality of hematology publications. © 2014, Iranian Pediatric Hematology and Oncology Society. All rights reserved.

Abbasi P.,Tabriz University of Medical Sciences | Shamsasenjan K.,Tabriz University of Medical Sciences | Shamsasenjan K.,Blood Transfusion Research Center | Akbari A.A.M.,Tabriz University of Medical Sciences | And 3 more authors.
Cell Journal | Year: 2015

Objective: The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins whose functions as transcription factors regulate gene expressions. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. This study attempts to determine the effect of baicalin, a PPARγ activator, on erythroid differentiation of cluster of differentiation 133+ (CD133+) cord blood hematopoietic stem cells (HSCs). Materials and Methods: In this experimental study, in order to investigate the effects of the PPARγ agonists baicalin and troglitazone on erythropoiesis, we isolated CD133+ cells from human umbilical cord blood using the MACS method. Isolated cells were cultured in erythroid-inducing medium with or without various amounts of the two PPARγ activators (baicalin and troglitazone). Erythroid differentiation of CD133+ cord blood HSCs were assessed using microscopic morphology analysis, flow cytometric analysis of erythroid surface markers transferrin receptor (TfR) and glycophorin A (GPA) and bycolony forming assay. Results: Microscopic and flow cytometric analysis revealed the erythroid differentiation of CD133+ cord blood HSCs under applied erythroid inducing conditions. Our flow cytometric data showed that the TfR and GPA positive cell population diminished significantly in the presence of either troglitazone or baicalin. The suppression of erythroid differentiation in response to PPARγ agonists was dose-dependent. Erythroid colony-forming ability of HSC decreased significantly after treatment with both PPARγ agonists but troglitazone had a markedly greater effect. Conclusion: Our results have demonstrated that PPARγ agonists modulate erythroid differentiation of CD133+ HSCs, and therefore play an important role in regulation of normal erythropoiesis under physiologic conditions. Thus, considering the availability and application of this herbal remedy for treatment of a wide range of diseases, the inhibitory effect of baicalin on erythropoiesis should be noted.

Behnava B.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Keshvari M.,Blood Transfusion Research Center | Miri S.M.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Elizee P.K.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Alavian S.-M.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Experimental and Clinical Hepatology | Year: 2011

Interferon, as an immunomodulatory agent, may be responsible for reactivation of Brucellosis in immunocompromised patients such as subjects with thalassemia. We report a case of 52 year old man with brucellosis reactivation during the therapy with Pegylated Interferon-alpha for chronic HCV infection. History included: previous living in rural area, tangent with sheep and cattle, prolonged fever and night sweats. At 16 weeks of treatment patient was negative for HCV-RNA PCR but experienced flu-like syndrome. Afterwards, weight loss and positive serologic studies for brucellosis were present. Antibiotic therapy leaded to a good clinical response within a few days and for the six months later. In endemic region, the past history of brucellosis should be considered prior to start of Interferon-alpha therapy particularly in the immunocompromised hosts. © E&C Hepatology, 2011.

Keshvari M.,Blood Transfusion Research Center | Keshvari M.,Middle East Liver Disease Center | Alavian S.M.,Middle East Liver Disease Center | Sharaf H.,Middle East Liver Disease Center | And 2 more authors.
Hepatitis Monthly | Year: 2014

Background: Approximately 5% of hepatitis B virus (HBV) carriers are coinfected with hepatitis D virus (HDV). HBV/HDV coinfection is a major cause of cirrhosis and end stage liver disease in chronic HBsAg carriers. The only approved therapy for chronic hepatitis delta is interferon alpha (IFN α) in either pegylated or conventional forms. Although higher doses and longer durations of IFN α therapy in HBV/ HDV coinfected patients are currently applied, yet treatment response is low. Objectives: We aimed to determine the efficacy of IFN α-2b therapy in patients with HBV/HDV coinfection. Patients and Methods: In this cross sectional study, 20 HBsAg carriers with positive Anti-HDVAb and RT-PCR for HDV RNA were recruited and treated for three year duration with 5 million units (MU) of IFN α-2b, three times weekly or one year with 5 MU of IFN α-2b daily. Sustained virological response (SVR) was defined as a negative qualitative HDV RT-PCR, 6 months after treatment cessation. Results: Overall, 3 (15%) subjects achieved SVR, 10 cases (50%) relapsed after treatment cessation and 7 (35%) patients did not clear HDV during the treatment. Conclusions: HDV coinfection with HBV had very low response rate to high doses and long durations of IFN α-2b therapy. © 2014, Kowsar Corp.; Published by Kowsar Corp.

Hosseini E.,Monash University | Hosseini E.,Blood Transfusion Research Center | Schwarer A.P.,Monash University | Jalali A.,Tehran University of Medical Sciences | And 2 more authors.
Leukemia Research | Year: 2013

Since relapse following allogeneic hematopoietic stem cell transplantation (HSCT) can be due to the escape of the residual malignant cells from the graft- versus-leukemia (GvL) effect and given the role of NK cells in GvL and the importance of HLA-E in the modulation of NK cell function, we investigated whether polymorphisms of HLA-E molecule could impact on the incidence of relapse and the improvement of Disease-free Survival (DFS) after allogeneic HSCT. The study group included 56 pairs of donors and patients with malignant hematological disorders undergoing HLA-E matched allogeneic HSCT. The median follow-up was 43.6 (range 20.5-113.1) months. They were genotyped for HLA-E locus using a sequence-specific primer (SSP)-PCR. We found a lower incidence of relapse (p= 0.02) in the patients with HLA-E* 0103/0103 genotype compared to those with other genotypes of HLA-E. We also showed an association between HLA-E* 0103/0103 genotype and a better DFS (p= 0.001). Our results suggest a protective role for HLA-E* 0103/0103 genotype against relapse and an association between this genotype and an improved DFS following HLA-E matched allogeneic HSCT. © 2013 Elsevier Ltd.

Ghasemzadeh M.,Monash University | Ghasemzadeh M.,Blood Transfusion Research Center | Hosseini E.,Blood Transfusion Research Center
Thrombosis Research | Year: 2013

Platelet activation is known to be associated with the release of a vast array of chemokines and proinflammatory lipids which induce pleiotropic effects on a wide variety of tissues and cells, including leukocytes. During thrombosis, the recruitment of leukocytes to activated platelets is considered an important step which not only links thrombosis to inflammatory responses but may also enhance procoagulant state. This phenomenon is highly regulated and influenced by precise mutual interactions between the cells at site of vascular injury and thrombi formation. Platelet-leukocyte interaction involves a variety of mediators including adhesion molecules, chemokines and chemoattractant molecules, shed proteins, various proinflammatory lipids and other materials. The current review addresses the detailed mechanisms underlying platelet-leukocyte crosstalk. This includes their adhesive interactions, transcellular metabolisms, induced tissue factor activity and neutrophil extracellular traps formation as well as the impacts of these phenomena in modulation of the proinflammatory and procoagulant functions in a reciprocal manner that enhances the physiological responses. © 2012 Elsevier Ltd.

Ziaei-Hezarjaribi H.,Mazandaran University of Medical Sciences | Ghaffarifar F.,Tarbiat Modares University | Dalimi-Asl A.,Tarbiat Modares University | Sharifi Z.,Blood Transfusion Research Center | Niaz-Jorjani O.,Golestan University of Medical Sciences
Journal of Mazandaran University of Medical Sciences | Year: 2014

Background and purpose: Previous Research shows the use of plasmids containing genes TSA to be useful as vaccines for Leishmania major. Recently, the role of interleukin-22 (IL-22) in tissue repair has been demonstrated. In this research, the effect of IL-22 on encoding TSA gene of Leishmania major in BALB/c mice was assessed.Materials and methods: pcDNA3 plasmid containing the gene encoding TSA protein (pcTSA) of Leishmania major, along with the cytokine IL-22 was used. 60 BALB/c mice were divided to 4 groups of 15. Control groups received pcDNA3 and PBS and a group was vaccinated intramuscularly with the TSA gene containing plasmid. Fourth group received plasmid containing the gene for the TSA and IL-22 protein. IL-4 and interferon gamma (IFN-γ) levels (MTT test) were used to evaluate the cellular immunity and IgG2a, IgG1 and Total IgG levels [enzyme-linked immunosorbent assay (ELISA) method] to evaluate the humoral immunity. Measuring the diameter of the lesions and the age and weight of the mice was performed.Results: The simultaneous use of plasmid containing the gene encoding protein TSA and IL-22 significantly increased the mean level of IFN-γ and reduced the mean level of IL-4 compared to the other groups. While the mortality rate at 27th week after intervention was 100 % in the control group, the surveillance rates of pcTSA and pcTSA + IL-22 groups were 80%. pcTSA + IL-22 group had the highest weight in 30th week. pcTSA + IL-22 group had significantly smaller lesions compared to control and pcTSA groups.Conclusion: Results show the efficacy of pcTSA + IL-22 in improving the vaccination of cutaneous leishmaniasis. © 2014 Mazandaran University of Medical Sciences. All rights reserved.

PubMed | Blood Transfusion Research Center
Type: Journal Article | Journal: Iranian journal of allergy, asthma, and immunology | Year: 2012

The non-classical MHC class-I mainly involves in the regulation of innate immune responses where HLA-E plays a significant role in the cell identification by natural killer cells. HLA-E is a main regulatory ligand for natural killer cells and given the importance of these effector cells in hematopoietic stem cell transplantation, we investigated the effect of HLA-E polymorphisms on post-hematopoietic stem cell transplantation outcomes. The study group included 56 donor-patient pairs with underlying malignant hematological disorders undergoing HLA-E matched allogeneic hematopoietic stem cell transplantation. They were genotyped for HLA-E locus using a sequence specific primer-polymerase chain reaction. The median follow-up was 20.6 months (range 0.2-114.8) and the parameters assessed were acute and chronic graft-versus-host disease and overall survival. We showed a lower frequency of acute graft-versus-host disease (grade II or more; p=0.02) and chronic graft-versus-host disease (extensive; p=0.04) in the patients with HLA-E*0103/0103 genotype compared to other genotypes of HLA-E. There was also an association between HLA-E*0103/0103 and improved overall survival (p=0.001). Conclusively, our results suggest a protective role for HLA-E*0103/0103 genotype against acute graft-versus-host disease (grade II or more) and chronic graft-versus-host disease (extensive) as well as an association between this genotype and a better overall survival after HLA-E matched allogeneic hematopoietic stem cell transplantation.

PubMed | Tabriz University of Medical Sciences, Tehran University of Medical Sciences, Blood Transfusion Research Center and Semnan University of Medical Sciences
Type: Journal Article | Journal: Cellular and molecular biology (Noisy-le-Grand, France) | Year: 2015

One of the most challenging aspects of colon cancer therapy is rapid acquisition of multidrug resistant phenotype. The multidrug resistance gene 1 (MDR1) product, p—glycoprotein (P—gp), pump out a variety of anticancer agents from the cell, giving rise to a general drug resistance against chemotherapeutic agents. The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of oxaliplatin—resistant SW480 human colon cancer cell line (SW480/OxR) to the chemotherapeutic drug oxaliplatin. SW480 cells were made resistant by continuous incubation with stepwise serially increased concentrations of oxaliplatin over a 6—months period. Resistance cell were subsequently transfected with specific MDR1 siRNA. Relative MDR1 mRNA expression was measured by Quantitative real—time PCR. Western blot analysis was performed to determine the protein levels of P—gp. The cytotoxic effects of oxaliplatin and MDR1 siRNA, alone and in combination were assessed using MTT and the number of apoptotic cells was determined with the TUNEL assay. MDR1 siRNA effectively reduced MDR1 expression in both mRNA and protein levels. MDR1 down—regulation synergistically increased the cytotoxic effects of oxaliplatin and spontaneous apoptosis SW480/OxR. Our data demonstrates that RNA interference could down regulate MDR1 gene expression and reduce the P—gp level, and partially reverse the drug resistance in SW480/OxR cells in vitro. Therefore, the results could suggest that MDR1 silencing may be a potent adjuvant in human colon chemotherapy.

PubMed | Blood Transfusion Research Center
Type: Journal Article | Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion | Year: 2012

The aim of this study was to investigate the association of anxiety and depression symptoms with health related quality of life (HRQoL) and sleep quality in patients with beta-thalassemia.In a cross-sectional study between 2006 and 2007, 292 thalassemic patients were assessed for symptoms of anxiety and depression (Hospital Anxiety Depression Scale; HADS), HRQoL (Short Form-36, SF-36) and quality of sleep (Pittsburgh Sleep Quality Index; PSQI). Linear regression models were used to determine possible predictive value of high anxiety and depressive symptoms on HRQoL and sleep quality, separately.Mental and physical quality of life scores were predicted by symptoms of depression and somatic comorbidities. Total sleep quality was predicted by anxiety symptoms and somatic comorbidities.Screening for anxiety and depression in patients with thalassemia is essential. Further studies should test if appropriate treatment of these conditions may improve patients HRQoL and sleep quality or not.

Loading Blood Transfusion Research Center collaborators
Loading Blood Transfusion Research Center collaborators